| The Biggest Streamer Just Rewrote Hollywood's Playbook |
|
| The industry's top platform signed a definitive agreement to buy a century-old studio, after the seller spins off its global networks unit. It's cash-and-stock deal with a 12–18 month clock, and promises of $2–3B in annual synergies and EPS accretion by year two. There's opportunity if you pay attention. |
|
| | Trade Smarter (Sponsored) | | | If you want to move beyond basic buy-and-hold, modern brokers now offer powerful tools built for everyday investors.
With intuitive dashboards, low-fee trades, fractional shares, and extended-hours access, it's easier than ever to test ideas, manage risk, and stay strategic.
Whether you're leveling up your approach or want more flexibility, these platforms give you the range to take the next step.
SEE YOUR OPTIONS |
|
| | | | Ulta Beauty | ULTA | | Price: $589.30 | Ulta's post-print rip wasn't a meme; it was fundamentals. Double-digit sales growth, comps re-accelerating, and a guidance raise across sales, margins, and EPS says beauty's demand curve still bends in Ulta's favor. | Mix helps: prestige plus mass, salon services, and wellness broaden the basket and steady traffic across income tiers. | Gross margin ticked higher on lower shrink and better merchandise margin while opex rose—store payroll, incentives, tech—tempering operating margin near-term. | That reinvestment is the tell: Ulta is pressing its moat while category momentum is strong. | Valuation isn't cheap at record highs, but leadership, loyalty economics, and a long runway in omnichannel + selective international make "expensive" more relative than absolute. | Why it matters for you: Watch comps and gross margin quality (promotions vs. mix). If operating margin creeps back toward the low-12s with traffic intact, multiple pressure eases. | Dips on profit-taking after a vertical move often set better entries than chasing fresh highs. |
|
| | Amgen | AMGN | | Price: $321.23 | The obesity drumbeat is getting louder, and Amgen just picked up more buy-side ears. | An upgrade cycle is leaning on early MariTide data (monthly or less frequent dosing, up to ~20% weight loss in Phase 2) and improving fundamentals. | Layer in full approval for IMDELLTRA in small-cell lung cancer and fresh outcomes data from Repatha, and you've got a diversified pipeline + portfolio story with optionality in the category investors care about most. | Timelines still matter. Obesity revenue is a later-'26+ conversation, and manufacturing, access, and head-to-head efficacy vs. incumbents must prove out. | But the setup with a solid balance sheet, growing cash flows, and a 2.8–2.9% dividend lets investors hold through readouts without paying peak hype multiples.
Why it matters for you: Focus on MariTide dosing profile, safety durability, and Phase 3 design, plus manufacturing scale plans. | If the path to commercial supply firms up while legacy franchises hold, AMGN's multiple can drift higher before obesity dollars actually hit. |
|
| | Hidden Opportunity (Sponsored) | | | A cluster of industry giants now sits at valuations completely misaligned with their operating performance.
Multi-year contracts, surging cash flow, and newly profitable segments signal expansion, yet the market discounts them like cyclical laggards.
This setup has historically produced outsized returns for early movers.
See the seven names while this anomaly still exists.
(By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time. - Privacy Policy) |
|
| | Albemarle | ALB |  | amen/ |
| Price: $127.20 | Lithium sentiment turned on a dime, and Albemarle is back in the conversation. | Upgrades cite a 2026-onward market deficit as grid storage accelerates and Western capacity lags. | For ALB, the lever is price + mix against a rightsized cost base after a brutal downcycle. | Q3 surprised to the less-bad side, and a string of target hikes suggests the Street is walking estimates up on ASP improvement and mid-cycle EBITDA power. | The catch is lithium is famously cyclical and globally contested. China's supply response, project slippage, and permitting drama can whipsaw assumptions fast. | Still, with valuation reset and the demand stack (EVs plus stationary storage) broadening, the asymmetry looks better than it did a year ago. | Why it matters for you: Watch realized pricing, contract tenor, and capex discipline. | If ALB converts price upticks into EBITDA without over-building, the re-rating story has legs; if prices stall and costs creep, rallies will be sold. |
|
| | Seagate Technology | STX | | Price: $285.41 | When the data center tide rises, high-capacity HDDs float. STX sits in a practical duopoly, and hyperscaler demand for cold and warm storage, fueled by AI training, inference, and ever-fatter datasets, has pulled pricing and mix higher. | The bull case is straightforward with HAMR roadmaps, disciplined supply, and richer nearline drives expand gross margins, while a string of Buy ratings + target raises telegraph confidence into '26. | The bear case is also familiar: cyclicality, hyperscaler procurement lumpiness, and SSD substitution chatter. | For now, the cash engine is switched on (dividend in tow), and operating leverage is doing its job as volumes normalize off the trough. | Why it matters for you: Track nearline exabytes shipped, ASPs, and HAMR yield commentary. | If Seagate hits its tech milestones and hyperscaler orders stay broad-based, the multiple can stay elevated longer than value purists expect. |
|
| | Warner Bros. Discovery | WBD | | Price: $27.23 | There's a deal on the table from Netflix to buy the giant. But, a definitive agreement doesn't mean a done deal. | Step one: separate Discovery Global into a standalone networks company (CNN, sports, linear properties). | Step two: close a cash-and-stock sale of the Warner Bros. studio, HBO, and HBO Max to Netflix at $27.75 per WBD share (subject to the collar). | The industrial logic favors distribution + library scale, theatrical continuity, and a cleaner cap table for what remains. | On paper, Netflix's promise of multi-billion cost synergies and accretion is the carrot; antitrust, timing drift, and integration complexity are the stick. | For WBD holders, the path to value is clearer than it's been in years, but it is a path, through regulatory reviews, spin mechanics, and potential portfolio tweaks. | Why it matters for you: Track regulatory milestones, spin timing, and the final mix of cash vs. stock. | Spreads can open on headlines; disciplined add-on entries usually appear around process wobble, not victory laps. |
|
| | Trivia: Which animal appears on the reverse of the Australian $1 coin? | |
|
| | Stat of the Day: $160 trillion
U.S. household net worth has climbed ~6× in 30 years to a record ~$160T. That wealth effect supports discretionary spend (beauty, travel, live events) and deepens capital pools funding AI and energy transitions. | Final Take | WBD's proposed split-and-sell gives holders a clearer map to value, even if the route winds through regulators. | Ulta is executing into strength, Amgen pairs a real dividend with real optionality, Albemarle is a levered bet on a tighter lithium tape, and Seagate is a clean way to play the storage side of AI's appetite. | Lean into backlogs, cost discipline, and cash flow; add on red, sip coffee on green, and let the catalysts compound. |
|
| Best Regards,
—Noah Zelvis
Everyday Alpha |
|
